PedAM
Pediatric Disease Annotations & Medicines
| Disease | polycythemia vera |
| Phenotype | C0001815|myelofibrosis |
| Sentences | 6 |
| PubMedID- 23555782 | The result that homozygosity for jak2v617f is a risk factor for bt in pmf parallels the finding that accumulation of jak2 mutated alleles contributes to transformation into myelofibrosis of patients with polycythemia vera [21]. |
| PubMedID- 21749449 | The jak2v617f allele burden and stat3- and stat5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis. |
| PubMedID- 23787440 | These results suggest that myelofibrosis in polycythemia vera represents a form of progression characterized by profound genetic damage whereas in primary myelofibrosis it is an intrinsic part of the phenotypic manifestation of the disease, not necessarily associated with adverse cytogenetics. |
| PubMedID- 25832853 | polycythemia vera (pv), along with primary myelofibrosis (mf) and essential thrombocythemia (et), is a classic philadelphia chromosome-negative myeloproliferative neoplasm (mpn) characterized primarily by an increased red blood cell mass [1–5]. |
| PubMedID- 25189724 | Essential thrombocythemia (et) and primary myelofibrosis (pmf), together with polycythemia vera (pv) are phildelphia-negative (ph-neg) classical myeloproliferative neoplasms (mpn). |
| PubMedID- 20650526 | Jak2(v617f) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. |
Page: 1